NCT04439305 · Interventional trial
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
Overall registry status Withdrawn
Phase 2
Conditions Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma
Delaware Valley sites
- ECOG-ACRIN Cancer Research Group · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory